文献速递妇科

骶神经调节与onabotulinumtoxinA治疗难治性急迫性尿失禁对大便失禁症状和性功能的影响比较

Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
PubMed 文献 · Am J Obstet Gynecol · 2019-06-15

本研究为一项随机试验的计划补充分析,纳入接受onabotulinumtoxinA(n=190)或骶神经调节(n=174)的难治性急迫性尿失禁女性,评估基线及6、12、24个月的大便失禁和性功能症状。结果显示两组在Vaizey评分和PISQ-12评分改善上均无差异,基线Vaizey≥12的亚组中两组均有临床意义的改善且组间无差异。

要点

  • 两组在6个月时Vaizey评分改善无差异:onabotulinumtoxinA组-1.9 vs 骶神经调节组-0.9,P=.07。
  • 两组在6个月时PISQ-12评分改善无差异:均为2.2,P=.99。
  • 基线Vaizey≥12亚组中两组均有临床意义改善,组间无差异。

核心结论

  • 在接受onabotulinumtoxinA或骶神经调节治疗的急迫性尿失禁女性中,大便失禁和性功能症状的改善无差异。
  • 基线时有显著大便失禁症状的女性在两种治疗后均有临床重要的症状改善,组间无差异。

研究设计与样本

  • 一项随机试验的计划补充分析,纳入接受onabotulinumtoxinA(n=190)或骶神经调节(n=174)的难治性急迫性尿失禁女性。
  • 在基线及6、12、24个月评估大便失禁和性功能症状。
  • 大便失禁症状采用St Mark's(Vaizey)大便失禁严重度量表测量,性功能症状采用PISQ-12和PISQ-IR测量。
  • 主要结局为基线与6个月之间Vaizey和PISQ-12评分的变化。
  • 采用意向性分析,使用重复测量混合模型估计各参数从基线的变化,并调整基线评分。

主要发现

  • 基线时平均Vaizey评分提示轻度大便失禁症状,onabotulinumtoxinA组与骶神经调节组无差异(7.6 ± 5.3 vs 6.6 ± 4.9,P = .07)。
  • 基线时性活跃女性比例(56% vs 63%,P = .25)、平均PISQ-12评分(33.4 ± 7.5 vs 32.7 ± 6.7,P = .55)及PISQ-IR子评分在两组间均无差异。
  • 6个月时大便失禁症状评分改善(Vaizey:-1.9,95%CI -2.6至-1.2 vs -0.9,95%CI -1.7至-0.2,P = .07)和性功能症状评分改善(PISQ-12:2.2,95%CI 0.7至3.7 vs 2.2,95%CI 0.7至3.7,P = .99)在两组间无差异。
  • 6个月时性活跃和非性活跃女性的性功能症状子评分改善在两组间无差异,12和24个月时结果类似。
  • 基线有临床显著大便失禁(Vaizey评分≥12)的亚组(onabotulinumtoxinA组33例,骶神经调节组22例)中,两组从基线至6个月均有临床意义的症状改善,组间无差异(-5.1,95%CI -7.3至-2.8 vs -5.6,95%CI -8.5至-2.6,P = .8)。

临床怎么用

  • 作者的发现可帮助临床医生为考虑难治性急迫性尿失禁治疗的女性提供咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with refractory urgency urinary incontinence can be treated with onabotulinumtoxinA or sacral neuromodulation. Little data exists on the comparative effects of treatment of refractory urgency urinary incontinence on other pelvic floor complaints, such as bowel and sexual function. OBJECTIVE: The objective of this study was to compare the impact of these treatments on fecal incontinence and sexual symptoms. METHODS: This was a planned supplemental analysis of a randomized trial in women with refractory urgency urinary incontinence treated with onabotulinumtoxinA (n = 190) or sacral neuromodulation (n = 174). Fecal incontinence and sexual symptoms were assessed at baseline and at 6, 12, and 24 months. Fecal incontinence symptoms were measured using the St Mark's (Vaizey) Fecal Incontinence severity scale. Sexual symptoms were measured using the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire-12 (PISQ-12) and the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). The PISQ-IR allows measurement of sexual symptoms in both sexually active and non-sexually active adults. Primary outcomes were change in Vaizey and PISQ-12 scores between baseline and 6 months. Secondary outcomes were change in PISQ-IR total and subscores between baseline and 6 months and change in Vaizey, PISQ-12, and PISQ-IR scores between baseline and 12 and 24 months. Intent-to-treat analysis was performed using repeated measures mixed model to estimate change in all parameters from baseline while adjusting for the baseline score. A subgroup analysis of women with clinically significant bowel symptoms was conducted based on baseline Vaizey score of ≥12. RESULTS: At baseline, mean Vaizey scores were indicative of mild fecal incontinence symptoms and were not different between onabotulinumtoxinA and sacral neuromodulation groups (7.6 ± 5.3 vs 6.6 ± 4.9, P = .07). The proportion of sexually active women (56% vs 63%, P = .25), mean PISQ-12 score (33.4 ± 7.5 vs 32.7 ± 6.7, P = .55), or PISQ-IR subscores were also not different between the onabotulinumtoxinA and sacral neuromodulation groups at baseline. There was no difference between women treated with onabotulinumtoxinA and those treated with sacral neuromodulation at 6 months in terms of improvement in fecal incontinence symptom score (Vaizey: -1.9, 95% confidence interval -2.6 to -1.2 vs -0.9, 95% confidence interval -1.7 to -0.2, P = .07) or sexual symptoms score (PISQ-12: 2.2, 95% confidence interval 0.7 to 3.7 vs 2.2, 95% confidence interval 0.7 to 3.7, P = .99). There was no difference in improvement between groups in the sexual symptom subscores in sexually active and non-sexually active women at 6 months. Similar findings were noted at 12 and 24 months. In a subgroup (onabotulinumtoxinA = 33 and sacral neuromodulation = 22) with clinically significant fecal incontinence at baseline (Vaizey score ≥12), there was a clinically meaningful improvement in symptoms in both groups from baseline to 6 months, with no difference in improvement between the onabotulinumtoxinA and sacral neuromodulation groups (-5.1, 95% confidence interval -7.3 to -2.8 vs -5.6, 95% confidence interval -8.5 to -2.6, P = .8). CONCLUSION: There were no differences in improvement of fecal incontinence and sexual symptoms in women with urgency urinary incontinence treated with onabotulinumtoxinA or sacral neuromodulation. Women with significant fecal incontinence symptoms at baseline had clinically important improvement in symptoms, with no difference between the treatments. Our findings can help clinicians counseling women considering treatment for refractory urgency urinary incontinence.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Andy UU, Amundsen CL, Honeycutt E, et al. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function. Am J Obstet Gynecol. 2019. PMID: 31211964. doi:10.1016/j.ajog.2019.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。